{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:07:02Z","timestamp":1789520822702,"version":"build-2803163510"},"reference-count":250,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX24_1852"],"award-info":[{"award-number":["KYCX24_1852"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373183"],"award-info":[{"award-number":["82373183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbcan.2026.189690","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:37:29Z","timestamp":1787269049000},"page":"189690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Universal CAR-T cell therapy: mechanisms and evasion strategies of bidirectional immune rejection"],"prefix":"10.1016","volume":"1881","author":[{"given":"Lu","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189690_bb0005","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1363139","article-title":"Trial watch: adoptively transferred cells for anticancer immunotherapy","volume":"6","author":"Fournier","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.bbcan.2026.189690_bb0010","doi-asserted-by":"crossref","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.bbcan.2026.189690_bb0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0020","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.3390\/ijms24076300","article-title":"CAR T cell therapy: a versatile living drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189690_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1335424","article-title":"Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic","volume":"15","author":"Smirnov","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2026.189690_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910365","article-title":"Revolutionizing CAR T-cell therapies: innovations in genetic engineering and manufacturing to enhance efficacy and accessibility","volume":"25","author":"Giorgioni","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189690_bb0040","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189690_bb0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189690_bb0050","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb0055","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jha2.479","article-title":"CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment","volume":"3","author":"Abecassis","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.bbcan.2026.189690_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK national CAR T panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbcan.2026.189690_bb0065","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb0070","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.bbcan.2026.189690_bb0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3349\/ymj.2007.48.1.11","article-title":"The HLA system: genetics, immunology, clinical testing, and clinical implications","volume":"48","author":"Choo","year":"2007","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.bbcan.2026.189690_bb0080","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood.2025028617","article-title":"Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies","volume":"146","author":"Socie","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0085","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2026.189690_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbcan.2026.189690_bb0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025030059","article-title":"Immune-mediated side effects of cancer immunotherapies","author":"Braun","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2026.102740","article-title":"Cell death pathways in graft-versus-host disease","volume":"99","author":"Pugel","year":"2026","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-025-02178-y","article-title":"Deep insight into cytokine storm: from pathogenesis to treatment","volume":"10","author":"Nie","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189690_bb0110","doi-asserted-by":"crossref","DOI":"10.1097\/MOT.0b013e328309ee31","article-title":"Pathways of major histocompatibility complex allorecognition","volume":"13","author":"Afzali","year":"2008","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.bbcan.2026.189690_bb0115","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11864-023-01061-8","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR cell therapy-neglected HvG effect","volume":"24","author":"An","year":"2023","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol. Today"},{"key":"10.1016\/j.bbcan.2026.189690_bb0125","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189690_bb0135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/tri.13549","article-title":"B cells in transplant tolerance and rejection: friends or foes?","volume":"33","author":"Schmitz","year":"2020","journal-title":"Transplant Int. Offi. J. Euro. Society Organ Transplant."},{"key":"10.1016\/j.bbcan.2026.189690_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1512494","article-title":"Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products","volume":"16","author":"Alfar","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0155","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.3389\/ti.2022.10465","article-title":"The role of fc gamma receptors in antibody-mediated rejection of kidney transplants","volume":"35","author":"Delpire","year":"2022","journal-title":"Transpl. Int."},{"key":"10.1016\/j.bbcan.2026.189690_bb0160","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41586-019-1537-0","article-title":"Structural basis of assembly of the human T cell receptor-CD3 complex","volume":"573","author":"Dong","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb0165","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/gt.2014.26","article-title":"TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer","volume":"21","author":"Berdien","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbcan.2026.189690_bb0175","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb0185","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1200\/JCO.2021.39.15_suppl.7516","article-title":"Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed\/refractory (r\/r) CD19+ NHL","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0190","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb0200","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol. Ther. J. Am. Society Gene Ther."},{"key":"10.1016\/j.bbcan.2026.189690_bb0205","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3324\/haematol.2019.233882","article-title":"Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: optimizing \u03b1\u03b2 T cell-depleted haploidentical hematopoietic stem cell transplantation","volume":"106","author":"Wiebking","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2026.189690_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004446","article-title":"Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression","volume":"10","author":"Mueller","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0215","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.omtn.2022.06.003","article-title":"Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells","volume":"29","author":"Madison","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbcan.2026.189690_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65267-0","article-title":"TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed\/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial","volume":"16","author":"Tseng","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb0225","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2427216122","article-title":"Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR\/Cas9 nuclease-engineered T cells","volume":"122","author":"Engel","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189690_bb0230","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1016\/j.ymthe.2025.08.032","article-title":"Orthogonal CRISPR systems for targeted integration and multiplex base editing enable nonviral engineering of allogeneic CAR-T cells","volume":"33","author":"Mikkelsen","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2026.189690_bb0235","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0240","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa2505478","article-title":"Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia","volume":"394","author":"Chiesa","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb0245","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1182\/blood-2023-181869","article-title":"Multiplex prime editing and PASSIGE TM for non-viral generation of an allogeneic CAR-T cell product","volume":"142","author":"Pomeroy","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0250","doi-asserted-by":"crossref","unstructured":"Hu, B. A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed\/refractory B cell non-Hodgkin lymphoma (r\/r B-NHL): updated phase 1 results from the ANTLER trial. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7025.","DOI":"10.1200\/JCO.2024.42.16_suppl.7025"},{"key":"10.1016\/j.bbcan.2026.189690_bb0255","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2021-147738","article-title":"Immunicy-1: targeting BCMA with cyad-211 to establish proof of concept of an shRNA-based allogeneic CAR T cell therapy platform","volume":"138","author":"Al-Homsi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102038","article-title":"Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform","volume":"34","author":"Rossi","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbcan.2026.189690_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1647433","article-title":"Multiplex engineering using microRNA-mediated gene silencing in CAR T cells","volume":"16","author":"Golinelli","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0270","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/bloodadvances.2017012823","article-title":"A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells","volume":"2","author":"Kamiya","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189690_bb0275","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2022-165822","article-title":"Development of an off-the-shelf chimeric antigen receptor (CAR)-T cell therapy for T-cell acute lymphoblastic leukemia (T-ALL) without gene editing","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114412","article-title":"Engineering CD3 subunits with endoplasmic reticulum retention signal facilitates allogeneic CAR T cell production","volume":"152","author":"Ebrahimiyan","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0285","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2023-189052","article-title":"Intracellular retention of tcr\u03b1\u03b2\/CD3 to generate novel allogeneic CAR-T cells (ThisCART19A) with enhanced antitumor potency for treating B-ALL","volume":"142","author":"Hu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106085","article-title":"Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells","volume":"26","author":"Ritacco","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.bbcan.2026.189690_bb0295","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2217\/imt-2021-0013","article-title":"Ruxolitinib, a JAK1\/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory gvhd mouse models","volume":"13","author":"Huarte","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbcan.2026.189690_bb0300","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189690_bb0305","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189690_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00295","article-title":"Metabolic targets for improvement of allogeneic hematopoietic stem cell transplantation and graft-vs.-host disease","volume":"10","author":"Tijaro-Ovalle","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.757836","article-title":"Recent metabolic advances for preventing and treating acute and chronic graft versus host disease","volume":"12","author":"Mohamed","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0320","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1314425","article-title":"Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects","volume":"6","author":"Ehx","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.bbcan.2026.189690_bb0325","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/bloodadvances.2021004225","article-title":"A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention","volume":"5","author":"Perez","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189690_bb0330","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2017-08-802249","article-title":"Vorinostat is victorious in GVHD prevention","volume":"130","author":"Holtan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0335","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1172\/JCI135754","article-title":"Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease","volume":"130","author":"Shrestha","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189690_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008663","article-title":"Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models","volume":"12","author":"Mei","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0345","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb0350","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/2767-9764.CRC-22-0175","article-title":"Clinical pharmacology and determinants of response to UCART19, an allogeneic anti-CD19 CAR-T cell product, in adult B-cell acute lymphoblastic leukemia","volume":"2","author":"Dupouy","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb0355","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1182\/blood-2021-153484","article-title":"Off-the-shelf, iPSC-derived CAR-NK cells multiplexed-engineered for the avoidance of allogeneic host immune cell rejection","volume":"138","author":"Mbofung","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0360","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.ymthe.2024.06.022","article-title":"Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells","volume":"32","author":"Maldini","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2026.189690_bb0365","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1038\/s41467-023-44176-0","article-title":"Cyclosporine a-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb0395","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1182\/blood-2021-149712","article-title":"Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell malignancies: an interim analysis","volume":"138","author":"Ramos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2026.02.008","article-title":"Stealth designs to overcome allorejection in engineered cell therapy","author":"Li","year":"2026","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0375","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb0380","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-025-03273-2","article-title":"LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells","volume":"44","author":"Zhu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"key":"10.1016\/j.bbcan.2026.189690_bb0385","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb0390","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008417","article-title":"Stealth transgenes enable CAR-T cells to evade host immune responses","volume":"12","author":"Grauwet","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0400","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-08657-0","article-title":"HIV immune evasin nef enhances allogeneic CAR T cell potency","volume":"640","author":"Perica","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb0405","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","article-title":"Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy","volume":"188","author":"Wu","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189690_bb0410","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1038\/s41467-025-63863-8","article-title":"Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xenograft mice","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb0415","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/iji.12527","article-title":"BSHI guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation","volume":"48","author":"Little","year":"2021","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.bbcan.2026.189690_bb0420","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb0425","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.4049\/jimmunol.2400491","article-title":"Hypoimmunogenic HLA-E single chain inhibits alloreactive immune responses","volume":"213","author":"Maldini","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013313","article-title":"Unlocking the promise of innate biology through the HLA-G\/ILT2\/ILT4 pathway","volume":"14","author":"Beers","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0435","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001998","article-title":"First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G","volume":"9","author":"Anna","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0445","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/eji.202049107","article-title":"Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis","volume":"51","author":"Guo","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0450","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/cdd.2013.26","article-title":"Molecular mechanisms of natural killer cell activation in response to cellular stress","volume":"21","author":"Chan","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2026.189690_bb0455","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1038\/s41375-025-02767-4","article-title":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia","volume":"39","author":"Pollyea","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2026.189690_bb0460","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adj7970","article-title":"The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance","volume":"9","author":"Kilian","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0465","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","article-title":"Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells","volume":"5","author":"Wang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bbcan.2026.189690_bb0470","article-title":"Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells","author":"Hammer","year":"2023","journal-title":"bioRxiv: Prepr. Serv. Biol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0475","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb0480","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb0485","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41551-023-01133-y","article-title":"Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts","volume":"8","author":"Harding","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bbcan.2026.189690_bb0490","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41551-024-01282-8","article-title":"Ablation of FAS confers allogeneic CD3- CAR T cells with resistance to rejection by T cells and natural killer cells","volume":"8","author":"Menegatti","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bbcan.2026.189690_bb0495","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/2326-6066.CIR-23-1001","article-title":"Overexpression of an engineered SERPINB9 enhances allogeneic T-cell persistence and efficacy","volume":"12","author":"Teo","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb0500","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41587-022-01540-7","article-title":"Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression","volume":"41","author":"Gravina","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0505","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"Mo","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0510","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u2018off-the-shelf\u2019 fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2026.189690_bb0520","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0515","article-title":"Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30+ lymphoma","volume":"32","author":"Quach","year":"2024","journal-title":"Mol. Ther., Oncol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0525","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0530","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb0535","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.medj.2022.10.003","article-title":"A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the japanese population","volume":"4","author":"Yoshida","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.bbcan.2026.189690_bb0540","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1073\/pnas.1902566116","article-title":"Generation of hypoimmunogenic human pluripotent stem cells","volume":"116","author":"Han","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189690_bb0545","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbcan.2026.189690_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1757174","article-title":"Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8\u03b1\u03b2 CAR-T cells","volume":"17","author":"Nianias","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0555","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/bioengineering10070857","article-title":"Assessing tumorigenicity in stem cell-derived therapeutic products: a critical step in safeguarding regenerative medicine","volume":"10","author":"Wang","year":"2023","journal-title":"Bioengineering"},{"key":"10.1016\/j.bbcan.2026.189690_bb0560","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2013.088997","article-title":"Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood","volume":"99","author":"Rodrigues","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2026.189690_bb0565","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21037\/sci.2019.09.01","article-title":"Lower T cell inhibitory receptor level in mononuclear cells from cord blood compared with peripheral blood","volume":"6","author":"Lin","year":"2019","journal-title":"Stem Cell Investig."},{"key":"10.1016\/j.bbcan.2026.189690_bb0570","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V94.9.3101","article-title":"Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes","volume":"94","author":"Kadereit","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0575","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2003-05-1732","article-title":"Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation","volume":"102","author":"Kaminski","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0580","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.exphem.2005.09.002","article-title":"Increased induction of allogeneic-specific cord blood CD4+CD25+ regulatory T (Treg) cells: a comparative study of na\u00efve and antigenic-specific cord blood Treg cells","volume":"33","author":"Chang","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0585","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1182\/blood-2025-4116","article-title":"Allogeneic CD19-directed CAR T-cell therapy derived from umbilical cord blood for relapsed acute lymphoblastic leukemia","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0590","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood.V99.6.2009","article-title":"Epstein-barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy","volume":"99","author":"Rossig","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0595","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0600","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/mt.2014.192","article-title":"Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells","volume":"23","author":"Melenhorst","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2026.189690_bb0605","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-017-0469-0","article-title":"Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I\/II multicenter clinical trial","volume":"10","author":"Qian","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0610","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0615","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0620","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41586-023-06525-3","article-title":"Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate V\u03b39V\u03b42 T cells","volume":"621","author":"Yuan","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb0625","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s002620100190","article-title":"Role of adhesion molecules in recruitment of Vdelta1 T cells from the peripheral blood to the tumor tissue of esophageal cancer patients","volume":"50","author":"Thomas","year":"2001","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2026.189690_bb0630","doi-asserted-by":"crossref","DOI":"10.20892\/j.issn.2095-3941.2025.0072","article-title":"Malignant ascites enhance \u03b3\u03b4 T cell cytotoxicity toward ovarian cancer via chemokine-mediated recruitment","author":"Yang","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb0635","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1093276","article-title":"NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human \u03b3\u03b4 T cells: modulation by temozolomide and a disintegrin and metalloproteases 10 and 17 inhibitors","volume":"5","author":"Chitadze","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2026.189690_bb0640","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1282758","article-title":"Gamma\/delta T cells as cellular vehicles for anti-tumor immunity","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0645","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1182\/blood-2009-07-234211","article-title":"Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement","volume":"116","author":"Maniar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0650","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0655","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Kp","year":"2022","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0660","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005400","article-title":"Generation and proof-of-concept for allogeneic CD123 CAR-delta one T (DOT) cells in acute myeloid leukemia","volume":"10","author":"S\u00e1nchez Mart\u00ednez","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0665","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2026.189690_bb0670","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0675","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.51","article-title":"MAIT cells: new guardians of the liver","volume":"5","author":"Kurioka","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0680","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/ncomms4866","article-title":"Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCR\u03b2 repertoire","volume":"5","author":"Lepore","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb0685","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/mi.2016.39","article-title":"Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals","volume":"10","author":"Chen","year":"2017","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0690","article-title":"Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy","volume":"9","author":"M","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0695","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/eji.201343509","article-title":"CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner","volume":"44","author":"Ussher","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0700","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1016\/j.celrep.2019.08.050","article-title":"TCR and inflammatory signals tune human MAIT cells to exert specific tissue repair and effector functions","volume":"28","author":"Leng","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189690_bb0705","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.4049\/jimmunol.1700615","article-title":"Activation of human mucosal-associated invariant T cells induces CD40L-dependent maturation of monocyte-derived and primary dendritic cells","volume":"199","author":"Salio","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0710","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1038\/s41467-021-25009-4","article-title":"MAIT cells regulate NK cell-mediated tumor immunity","volume":"12","author":"Petley","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb0715","article-title":"Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity","volume":"14","author":"Yr","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189690_bb0720","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201605","article-title":"Tissue-resident memory T cells in tumor immunity and immunotherapy","volume":"218","author":"Ok\u0142a","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb0725","doi-asserted-by":"crossref","DOI":"10.1038\/srep20358","article-title":"Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients","volume":"6","author":"Ling","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189690_bb0730","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005902","article-title":"Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy","volume":"11","author":"Shi","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0735","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17\u2013secreting T cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0740","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.bulcan.2021.07.003","article-title":"Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy","volume":"108","author":"Bohineust","year":"2021","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0745","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4049\/jimmunol.2100856","article-title":"Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy","volume":"209","author":"Dogan","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0750","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","article-title":"Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin","volume":"186","author":"Ruf","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189690_bb0755","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2159-8290.CD-19-0569","article-title":"MAIT cells promote tumor initiation, growth, and metastases via tumor MR1","volume":"10","author":"Yan","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189690_bb0760","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jhep.2025.06.006","article-title":"Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD","volume":"83","author":"Deschler","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0765","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140074","article-title":"Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection","volume":"6","author":"Parrot","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbcan.2026.189690_bb0770","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1367","article-title":"Circulating CD8+ mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patients","volume":"11","author":"Vorwald","year":"2022","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0775","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2326-6066.CIR-20-0925","article-title":"Activating mucosal-associated invariant T cells induces a broad antitumor response","volume":"9","author":"Ruf","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb0780","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1126\/science.278.5343.1626","article-title":"CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides","volume":"278","author":"Kawano","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189690_bb0785","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.17.1.297","article-title":"The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids","volume":"17","author":"Porcelli","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0790","article-title":"Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers","volume":"25","author":"Li","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.bbcan.2026.189690_bb0795","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13287-022-02787-2","article-title":"Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.bbcan.2026.189690_bb0800","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clim.2010.10.005","article-title":"Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans","volume":"140","author":"Metelitsa","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0805","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1176724","article-title":"Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes","volume":"14","author":"Look","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0810","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0815","doi-asserted-by":"crossref","unstructured":"Liu T.-Y. et al. Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur. J. Immunol. doi:https:\/\/doi.org\/10.1002\/eji.200737838.","DOI":"10.1002\/eji.200737838"},{"key":"10.1016\/j.bbcan.2026.189690_bb0820","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI37869","article-title":"V\u03b124-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189690_bb0825","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.celrep.2018.02.058","article-title":"Bimodal CD40\/fas-dependent crosstalk between iNKT cells and tumor-associated macrophages impairs prostate cancer progression","volume":"22","author":"Cortesi","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189690_bb0830","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0835","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189690_bb0840","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/ijms22031096","article-title":"Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma","volume":"22","author":"Poels","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189690_bb0845","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0850","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","article-title":"Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb0855","doi-asserted-by":"crossref","unstructured":"Li, Y.-R. et al. Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell\u2013engineered mesothelin-redirected CAR-NKT cells. Proc. Natl. Acad. Sci. USA 122, e2517786122.","DOI":"10.1073\/pnas.2517786122"},{"key":"10.1016\/j.bbcan.2026.189690_bb0860","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","article-title":"Targeting triple-negative breast cancer using cord-blood CD34+ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0865","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.bbcan.2026.189690_bb0870","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/77513","article-title":"Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression","volume":"6","author":"Zhang","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb0875","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13046-018-0756-9","article-title":"Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy","volume":"37","author":"Chen","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb0880","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-17-2228","article-title":"Allogeneic human double negative T cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms","volume":"24","author":"Lee","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb0885","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2023-182920","article-title":"Double-negative T cells attenuate acute graft-versus-host disease by modulating CD4 + T cell activation post-allo-HSCT","volume":"142","author":"Pan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0890","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1002\/ajh.26564","article-title":"Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: a first-in-human phase I study","volume":"97","author":"Tang","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0895","first-page":"8014","article-title":"Antitumor activity mediated by double-negative T cells","volume":"63","author":"Young","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb0900","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-18-2291","article-title":"Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer","volume":"25","author":"Lee","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb0905","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-019-0507-2","article-title":"Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15","volume":"7","author":"Yao","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0910","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13046-019-1126-y","article-title":"Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade","volume":"38","author":"Fang","year":"2019","journal-title":"J. exp. clin. cancer res.: CR"},{"key":"10.1016\/j.bbcan.2026.189690_bb0915","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1182\/bloodadvances.2023011739","article-title":"Double-negative T cells utilize a TNF\u03b1\u2013JAK1\u2013ICAM-1 cytotoxic axis against acute myeloid leukemia","volume":"8","author":"Tin","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189690_bb0920","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007277","article-title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","volume":"11","author":"Fang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb0925","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0930","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.70022","article-title":"A preclinical study of allogeneic CD19 chimeric antigen receptor double-negative T cells as an off-the-shelf immunotherapy drug against B-cell malignancies","volume":"13","author":"Wang","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0935","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1182\/blood-2024-206995","article-title":"A novel bispecific allogeneic CAR-DNT cells targeting BCMA and CD19 for immunotherapy","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0940","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb0945","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbcan.2026.189690_bb0950","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted Ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.bbcan.2026.189690_bb0955","first-page":"5702","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189690_bb0960","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2021.09.003","article-title":"Optimization of AAV6 transduction enhances site-specific genome editing of primary human lymphocytes","volume":"23","author":"Rogers","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bbcan.2026.189690_bb0965","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bbcan.2026.189690_bb0970","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.ymthe.2024.12.019","article-title":"mRNA-LNPs induce immune activation and cytokine release in human whole blood assays across diverse health conditions","volume":"33","author":"Nguyen","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2026.189690_bb0975","article-title":"Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy","volume":"17","author":"Zhang","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0980","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T-cells in paediatric and adult B-acute lymphoblastic leukaemia: results of two phase I studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2026.189690_bb0985","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bbcan.2026.189690_bb0990","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb0995","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2021-146038","article-title":"ALPHA study: ALLO-501 produced deep and durable responses in patients with relapsed\/refractory non-hodgkin\u2019s lymphoma comparable to autologous CAR T","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1000","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189690_bb1005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-138594","article-title":"Preliminary results of balli-01: a phase I study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 chimeric antigen receptor) in adult patients with relapsed or refractory (R\/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL)","volume":"136","author":"Jain","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1010","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood-2023-186570","article-title":"Preliminary results of nathali-01: a first-in-human phase I\/IIa study of UCART20x22, a dual allogeneic CAR-T cell product targeting CD20 and CD22, in relapsed or refractory (R\/R) non-hodgkin lymphoma (NHL)","volume":"142","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1015","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb1020","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/bloodadvances.2021006232","article-title":"CRISPR\/Cas9 genome-edited universal CAR T cells in patients with relapsed\/refractory lymphoma","volume":"6","author":"Guo","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189690_bb1025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.HS9.0000844368.41871.e3","article-title":"P370: early results of a safety and efficacy study of allogeneic truucar\u2122 Gc502 in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (r\/R B-all)","volume":"6","author":"Li","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.bbcan.2026.189690_bb1030","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 allogeneic CRISPR-Cas9-engineered CAR T cells in patients (pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the phase 1 dose escalation carbon study","volume":"140","author":"McGuirk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1035","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2024-203563","article-title":"CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T cell with novel potency edits: data from phase 1 dose escalation study in patients with relapsed or refractory B-cell malignancies","volume":"144","author":"Ghobadi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb1045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2020-142262","article-title":"The safety and efficacy of a CRISPR\/Cas9-engineered universal CAR-T cell product (CTA101) in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"136","author":"Hu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1050","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood-2023-178723","article-title":"Phase 1\/2 dose-escalation\/dose-expansion study of anti-CD7 allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/ lymphoblastic lymphoma (T-ALL\/LBL)","volume":"142","author":"Ghobadi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1055","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2021-150609","article-title":"Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in patients with relapsed\/refractory B-cell malignancies","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1060","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2022-167194","article-title":"Interim phase I clinical data of FT819-101, a study of the first-ever, off-the-shelf, iPSC-derived TCR-less CD19 CAR T-cell therapy for patients with relapsed\/refractory B-cell malignancies","volume":"140","author":"Mehta","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1065","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/bloodadvances.2024015157","article-title":"Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies","volume":"9","author":"Shahid","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189690_bb1070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","article-title":"CD30.CAR-modified epstein-barr virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1075","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1080","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2022-157400","article-title":"A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma Delta1 (\u03b3\u03b4) T cells in adults with B-cell malignancies","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102516","article-title":"CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study","volume":"70","author":"Xiao","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bbcan.2026.189690_bb1090","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT011","article-title":"Abstract CT011: a phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell Renal cell carcinoma (ccRCC)","volume":"83","author":"Srour","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb1095","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189690_bb1100","article-title":"50P phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies","volume":"24","author":"Oh","year":"2024","journal-title":"Immuno-Oncol. Technol."},{"key":"10.1016\/j.bbcan.2026.189690_bb1105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2021.39.3_suppl.74","article-title":"Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC","volume":"39","author":"Prenen","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189690_bb1110","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","article-title":"Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma","volume":"31","author":"Quintarelli","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb1115","article-title":"Intrathecal allogeneic B7-H3\u2013targeted CAR \u03b3\u03b4 T cells for leptomeningeal metastasis from solid tumors: safety, efficacy, and immunologic dynamics in a phase I trial","volume":"OF1\u2013OF13","author":"Ma","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189690_bb1125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2026.189690_bb1130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb1135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adz0529","article-title":"ZAP327 signaling domain-driven chimeric antigen receptor generates robust and long-term antitumor immunity in mouse models","volume":"17","author":"Liu","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb1140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb1145","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb1150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189690_bb1155","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","article-title":"Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy","volume":"576","author":"Wei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb1160","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn5647","article-title":"Enhanced T cell effector activity by targeting the mediator kinase module","volume":"378","author":"Freitas","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189690_bb1165","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","article-title":"RASA2 ablation in T cells boosts antigen sensitivity and long-term function","volume":"609","author":"Carnevale","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb1170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb1175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"C-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb1180","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","article-title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells","volume":"22","author":"Seo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2026.189690_bb1185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb1190","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/2159-8290.CD-22-1350","article-title":"SUV39H1 ablation enhances Long-term CAR T function in solid tumors","volume":"14","author":"L\u00f3pez-Cobo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189690_bb1195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-017-0227-4","article-title":"Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy","volume":"5","author":"Urak","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189690_bb1200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189690_bb1205","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189690_bb1210","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189690_bb1215","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.bbcan.2026.189690_bb1220","article-title":"Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers","author":"Steffin","year":"2024","journal-title":"Res Sq"},{"key":"10.1016\/j.bbcan.2026.189690_bb1225","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189690_bb1230","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189690_bb1235","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1038\/s41467-019-13007-6","article-title":"Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors","volume":"10","author":"Webber","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189690_bb1240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41551-024-01277-5","article-title":"Large DNA deletions occur during DNA repair at 20-fold lower frequency for base editors and prime editors than for Cas9 nucleases","volume":"9","author":"Hwang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bbcan.2026.189690_bb1245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41551-024-01233-3","article-title":"Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells","volume":"9","author":"Sousa","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bbcan.2026.189690_bb1250","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189690_bb1255","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/stcltm\/szae058","article-title":"Detection of residual pluripotent stem cells in cell therapy products utilizing droplet digital PCR: an international multisite evaluation study","volume":"13","author":"Yasuda","year":"2024","journal-title":"Stem Cells Transl. Med."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:20:22Z","timestamp":1789518022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":250,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0304419X26001629"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189690","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Universal CAR-T cell therapy: mechanisms and evasion strategies of bidirectional immune rejection","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189690"}}